Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ViewRay, Inc.
  6. News
  7. Summary
    VRAY   US92672L1070

VIEWRAY, INC.

(VRAY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Trends: Insider Adds to Selling Trend at ViewRay

06/10/2021 | 07:05am EDT


ę MT Newswires 2021
All news about VIEWRAY, INC.
07/26INSIDER TRENDS : ViewRay Insider Tax Sale Continues 90-Day Selling Trend
MT
07/15VIEWRAY : Announces Conference Call for Second Quarter 2021 Financial Results to..
PR
07/07VIEWRAY : Miami Cancer Institute Enrolls First Patients in Single-Fraction Stere..
PR
07/07ViewRay, Inc. Announces That Miami Cancer Institute Enrolled First Patients i..
CI
06/28VIEWRAY : Morgan Stanley Lifts ViewRay to Equal-Weight From Underweight, Price T..
MT
06/25VIEWRAY : Oppenheimer Adjusts ViewRay PT to $8 From $6, Maintains Outperform Rat..
MT
06/25VIEWRAY, INC.(NASDAQGM : VRAY) dropped from Russell 3000 Value Index
CI
06/25VIEWRAY, INC.(NASDAQGM : VRAY) dropped from Russell Microcap Value Index
CI
06/25VIEWRAY, INC.(NASDAQGM : VRAY) dropped from Russell 3000E Value Index
CI
06/25VIEWRAY, INC.(NASDAQGM : VRAY) dropped from Russell 2500 Value Index
CI
More news
Financials (USD)
Sales 2021 73,4 M - -
Net income 2021 -109 M - -
Net cash 2021 95,5 M - -
P/E ratio 2021 -9,84x
Yield 2021 -
Capitalization 1 077 M 1 077 M -
EV / Sales 2021 13,4x
EV / Sales 2022 8,74x
Nbr of Employees 236
Free-Float 96,5%
Chart VIEWRAY, INC.
Duration : Period :
ViewRay, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIEWRAY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 6,66 $
Average target price 7,41 $
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Scott William Drake President, Chief Executive Officer & Director
Zachary Stassen Chief Financial Officer
Daniel Jeffrey Moore Chairman
James F. Dempsey Chief Scientific Officer
Martin Fuss Chief Medical Officer
Sector and Competitors